New FDA Initiatives Aim to Spur Innovation

Manufacturers face challenges from FDA's plans to streamline the drug review and development processes aimed to spur innovation.

Related Content:

Quality SystemsRegulatory Oversight and CompliancePharmaceutical Technology-08-02-2003

ICH Q6B for Analytics

USP Opens Advanced Technology Lab in Maryland

EMA Is Tackling Vulnerabilities in the Supply Chain of Radiopharmaceuticals